Aclaris Therapeutics, Inc.
NASDAQACRS short interest surges 21.8% in one week to 9.7% of float, driven by skepticism over clinical pipeline progress.
Snapshot as of 19 Jul 2026
Aclaris Therapeutics reports Q1 results this morning with options traders running their most defensive positioning of the past year — even as the analyst community has rarely been more constructive on the stock. The…
Aclaris Therapeutics reports Q1 results tomorrow morning with a setup that cuts several ways at once: a fresh analyst initiation, a put/call ratio at its highest level in a year, and short sellers holding a meaningful…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACRS — free to start on ORTEX.
Sign up for free →Open ACRS on ORTEX